Its AmorphOX tablet matched the reference semaglutide tablet's bioavailability in an early animal study before any optimization, CEO Nikolaj Sørensen explains.
Recap by typeshit. Full story at Biostock.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
NBC reports, citing two people familiar with the plan, that it would let pharmacies temporarily compound popular peptides like BPC-157, despite FDA staff safety concerns.
Quartz reports on a large study suggesting weight loss drugs may reduce psychiatric hospital visits among people with schizophrenia.
Loading…